DLD Asset Management LP Purchases New Shares in ESSA Pharma Inc. $EPIX

Key Points

• DLD Asset Management LP has acquired a new position in ESSA Pharma Inc., purchasing 183,658 shares valued at approximately $290,000.
• ESSA Pharma recently reported an earnings per share (EPS) of ($0.09) for the quarter, exceeding the consensus estimate of ($0.17).
• The company is focused on developing small molecule drugs for the treatment of prostate cancer, with its lead candidate being EPI-7386.

DLD Asset Management LP bought a new position in shares of ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 183,658 shares of the company's stock, valued at approximately $290,000. DLD Asset Management LP owned 0.41% of ESSA Pharma at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Tang Capital Management LLC bought a new position in shares of ESSA Pharma during the 4th quarter worth approximately $7,697,000. Bank of America Corp DE lifted its stake in shares of ESSA Pharma by 10,153,775.0% during the 4th quarter. Bank of America Corp DE now owns 812,310 shares of the company's stock worth $1,454,000 after buying an additional 812,302 shares during the last quarter. Aldebaran Capital LLC lifted its stake in shares of ESSA Pharma by 43.2% during the 1st quarter. Aldebaran Capital LLC now owns 569,294 shares of the company's stock worth $899,000 after buying an additional 171,771 shares during the last quarter. Two Sigma Investments LP acquired a new stake in shares of ESSA Pharma during the 4th quarter worth about $378,000. Finally, Marshall Wace LLP acquired a new stake in shares of ESSA Pharma during the 4th quarter worth about $324,000. 75.12% of the stock is currently owned by institutional investors.

ESSA Pharma Stock Down 59.4%

Shares of NASDAQ EPIX traded down $1.1460 during mid-day trading on Monday, reaching $0.7840. 126,730,909 shares of the company were exchanged, compared to its average volume of 1,021,772. The company's 50-day simple moving average is $1.82 and its 200-day simple moving average is $1.72. The stock has a market capitalization of $37.09 million, a P/E ratio of -1.40 and a beta of 1.55. ESSA Pharma Inc. has a twelve month low of $0.7330 and a twelve month high of $7.88.

ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last posted its earnings results on Wednesday, August 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. As a group, equities research analysts expect that ESSA Pharma Inc. will post -0.42 EPS for the current year.

ESSA Pharma Announces Dividend

The company also recently declared a -- dividend, which was paid on Friday, August 22nd. Investors of record on Tuesday, August 19th were paid a $1.69 dividend. The ex-dividend date was Monday, August 25th.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.